Skip to content

FOCUS: A study for people with type 2 diabetes and eye disease

Type 2 Diabetes | Diabetic Retinopathy | Diabetic Complications

The FOCUS study is being done to see if a medicine called semaglutide can reduce the risk of retinopathy progression in people with type 2 diabetes.

null

Conditions de participation

  • Sexe:

    Any

  • Âges admissibles:

    18 to 90

Critères de participation

Inclusion Criteria:
18 years of age with type 2 diabetes
HbA1c 7-10%
History of diabetic eye disease
Exclusion Criteria:
None to list online.

Lieu de l'étude

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Caroline Lyster

[email protected]
780-248-1770
Primary Contact

Ruth Fazio

[email protected]
780-492-1098
Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: Pro00092168